ElevateBio BaseCamp: Delivering Genetic Medicines From Concept Through Commercialization

By Mike Paglia, Chief Technology Officer of BaseCamp

ElevateBio BaseCamp is a pioneering genetic medicine manufacturing platform designed to accelerate the development and commercialization of advanced therapies. As a first-of-its-kind genetic medicine foundry, BaseCamp integrates cutting-edge technology platforms with end-to-end cGMP manufacturing capabilities, enabling partners to bring transformative cell and gene therapies from concept to clinic with unprecedented speed and efficiency.

With over 300,000 square feet of dedicated biomanufacturing space across facilities in Waltham and Pittsburgh, BaseCamp supports a wide range of modalities including mRNA therapeutics, viral vectors, and cell therapies. Its robust infrastructure includes automated systems, scalable processes, and regulatory expertise, all certified to U.S. FDA and E.U. standards. Through strategic partnerships and a customer-centric approach, ElevateBio empowers biopharma innovators to streamline therapeutic development, reduce timelines, and scale novel technologies. The Life Edit platform further expands therapeutic possibilities by enabling precise gene editing across previously inaccessible genomic regions. With a proven track record of shortening IND timelines and optimizing manufacturing processes, ElevateBio BaseCamp stands as a trusted partner in the genetic medicine ecosystem, delivering quality, innovation, and commercial readiness.

This integrated model positions ElevateBio as a transformative force in redefining how genetic medicines are developed, manufactured, and delivered to patients.